Associated Papers
Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-Type FLT3 Acute Myeloid Leukemia/Myelodysplastic Neoplasms.
Chang S et al.
Case Reports in Hematology, 2025
Select a paper to view details